Table 4.
Clinicopathological characteristics of patients with pretreatment according to the KC
| Characteristics | Within KC (n = 31) | Beyond KC (n = 18) | p value |
|---|---|---|---|
| Age, years | 57 (22–69) | 55 (23–62) | 0.65 |
| Sex (male/female) | 25/6 | 12/6 | 0.27 |
| Etiology | 0.91 | ||
| Viral hepatitis C | 15 | 10 | |
| Viral hepatitis B | 10 | 5 | |
| Viral hepatitis C/B | 1 | 1 | |
| Others | 5 | 2 | |
| AFP, ng/mL | 51 (2–3,564) | 249 (3–212,220) | 0.28 |
| DCP, mAU/mL | 56 (2–400) | 374 (12–20,600) | 0.04 |
| Child-Pugh (A/B/C) | 15/16/0 | 9/9/0 | 0.91 |
| MELD | 11 (6–22) | 10 (4–17) | 0.37 |
| Maximum tumor size, cm | 3.3 (1–5) | 3 (1–26) | 0.23 |
| Tumors, n | 5 (2–10) | 16 (3–186) | 0.03 |
| Classification (well/mod./poor) | 0/23/8 | 3/9/6 | 0.03 |
| Microvascular invasion | 15 (48%) | 13 (72%) | 0.10 |
AFP, α-fetoprotein; DCP, des-gamma-carboxy prothrombin; MELD, model for end-stage liver disease.